Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-936559 in HIV-1 on Suppressive cART
NCT02028403Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2014
- Primary completion
- Nov 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BMS-936559 in human immunodeficiency virus type 1 infection (HIV-1) (8 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Occurrence of a Grade 3 or greater adverse event at Day 28, Occurrence of a Grade 1 or > AE of all incident adrenal insufficiency or adrenal crisis, myocarditis, pneumonitis, uveitis, immune-mediated hyperthyroidism or hypothyroidism at Day 28 and 2 more. Started Jun 2014; status: completed.
02
Drugs
BMS-936559
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02028403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02028403.